Vitiligo is a chronic disease characterized by dyschromic patches on the skin
and mucous membranes resulting from the destruction of functional melanocytes in
the epidermis. Its etiopathogenesis is unknown, but it is currently considered an
autoimmune disease. Vitamin D has been linked to Vitiligo due to its autocrine
immunoregulatory function in immune cells. The aim of the present study was to
analyze the serum levels of 25-hydroxyvitamin D in patients with Vitiligo and healthy
individuals without Vitiligo, considering the clinical and epidemiological characteristics
of the patients. An analytical cross-sectional study was carried out in the period from
2017 to 2021 in a public hospital of reference in Dermatology in the city of Belém,
where data were collected from 79 patients from the Vitiligo Group and 3,215
individuals from the No Vitiligo Group who had serum levels of 25-hydroxyvitamin D
The clinical-epidemiological variables in the Vitiligo Group were gender, age,
phototype, clinical form, disease duration, lesion extension, lesion activity, family
member, triggering emotional factor and education. The study sample consisted of
the prevalence of females (70.89%) with a mean age of 34.3 years for both sexes in
the Vitiligo Group. The majority (52.08%) of the Vitiligo Group had low serum levels
of 25-hydroxyvitamin D and 86.96% of the No Vitiligo Group had levels within the
normal range. However, no statistical differences were found in the 25-hydroxyvitamin D levels of the Vitiligo Group when compared to the No Vitiligo
Group. Finally, as in previous studies in the vitiligo population, lower levels of 25hydroxyvitamin D concentration were not found in relation to the general population.
|
